Formatted anti-tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis

Arthritis and Rheumatism

Volumn 54, Issue 6, 2006, Pages 1856-1866

  Coppieters, Ken ^a   Dreier, Torsten ^b   Silence, Karen ^b   De Haard, Hans ^b   Lauwereys, Marc ^b   Casteels, Peter ^b   Beirnaert, Els ^b   Jonckheere, Heidi ^b   Van De Wiele, Christophe ^c   Staelens, Ludovicus ^d   Hostens, Jeroen ^a   Revets, Hilde ^e   Remaut, Erik ^a   Elewaut, Dirk ^c   Rottiers, Pieter ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b ABLYNX NV   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALBUMIN; ETANERCEPT; IMMUNOGLOBULIN HEAVY CHAIN; INFLIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TN3 19.12; NANOBODIES; NANOBODY; TECHNETIUM 99M; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; ARTIODACTYLA; BINDING AFFINITY; DISEASE COURSE; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; IMMUNOGLOBULIN VARIABLE REGION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCINTILLATION CAMERA;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; CAMELIDS, NEW WORLD; HALF-LIFE; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MICE, INBRED BALB C; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745032737     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21827     Document Type: Article

References (42)

1. Tobin AM, Kirby B. TNFα inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005;19:47-57.
2. Stokkers PC, Hommes DW. New cytokine therapeutics for inflammatory bowel disease. Cytokine 2004;28:167-73.
3. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet 2000;356:1821-2.
4. Olsen NJ. Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
5. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2:364-71.
6. Chadd HE, Chamow SM. Therapeutic antibody expression technology. Curr Opin Biotechnol 2001;12:188-94.
7. Foxwell B, Andreakos E, Brennan F, Feldmann M, Smith C, Conron M. Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents. Ann Rheum Dis 2003;62 Suppl 2:ii90-3.
8. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363:446-8.
9. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 1997;414:521-6.
10. HH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol 2000;78:11-21.
11. Els Conrath K, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001;276:7346-50.
12. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, et al. Efficient cancer therapy with a Nanobody-based conjugate. Cancer Res 2004;64:2853-7.
13. Dumoulin M, Last AM, Desmyter A, Decanniere K, Canet D, Larsson G, et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 2003;424:783-8.
14. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002;277:35035-43.
15. Wunder A, Muller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003;170:4793-801.
16. Fiehn C, Muller-Ladner U, Gay S, Krienke S, Freudenberg-Konrad S, Funk J, et al. Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology (Oxford) 2004;43:1097-105.
17. Fiehn C, Neumann E, Wunder A, Krienke S, Gay S, Muller-Ladner U. Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo. Ann Rheum Dis 2004;63:884-6.
18. Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988;240:1038-41.
19. Ameloot P, Brouckaert P. Production and characterization of receptor-specific TNF muteins. Methods Mol Med 2004;98:33-46.
20. Sheehan KC, Ruddle NH, Schreiber RD. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol 1989;142:3884-93.
21. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77:510-4.
22. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
23. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 2003;37:1256-65.
24. Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL, et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng 1993;6:989-95.
25. Lawrence LJ, Kortt AA, Iliades P, Tulloch PA, Hudson PJ. Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments. FEBS Lett 1998;425:479-84.
26. Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, et al. Single-domain antibody fragments with high conformational stability. Protein Sci 2002;11:500-15.
27. Riechmann L, Muyldermans S. Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods 1999;231:25-38.
28. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174:1483-9.
29. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
30. Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res 2002;4 Suppl 2:S22-8.
31. Levick JR. Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum 1981;24: 1550-60.
32. Wilkinson P, Jeremy R, Brooks FP, Hollander JL. The mechanism of hypoalbuminemia in rheumatoid arthritis. Ann Intern Med 1965;63:109-14.
33. Ballantyne FC, Fleck A, Dick WC. Albumin metabolism in rheumatoid arthritis. Ann Rheum Dis 1971;30:265-70.
34. Niwa Y, Iio A, Niwa G, Sakane T, Tsunematsu T, Kanoh T. Serum albumin metabolism in rheumatic diseases: relationship to corticosteroids and peptic ulcer. J Clin Lab Immunol 1990;31:11-6.
35. Dixon FJ, Maurer PH, Deichmiller MP. Half-lives of homologous serum albumins in several species. Proc Soc Exp Biol Med 1953;83:287-8.
36. Andersson CE, Lonnroth IC, Gelin LJ, Moldawer LL, Lundholm KG. Pretranslational regulation of albumin synthesis in tumor-bearing mice: the role of anorexia and undernutrition. Gastroenterology 1991;100:938-45.
37. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003;197:315-22.
38. Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, et al, and the Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Clin Cancer Res 1999;5:753-9.
39. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980;283:666-8.
40. Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001;103:407-16.
41. Joosten LA, Helsen MM, Saxne T, van de Loo FA, Heinegard D, van den Berg WB. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-β blockade only ameliorates joint inflammation. J Immunol 1999;163:5049-55.
42. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002;98:456-62.